Guanfacine ER is an extended-release, non-stimulant medication used to treat ADHD in children and adolescents ages 6 to 17. Sold under the brand name Intuniv, it works differently from stimulant medications like methylphenidate or amphetamines. Instead of increasing dopamine activity, guanfacine ER targets a specific receptor in the prefrontal cortex, the brain region responsible for attention, impulse control, and working memory.
How Guanfacine ER Works in the Brain
Guanfacine ER strengthens communication between neurons in the prefrontal cortex. It does this by activating a receptor (called the alpha-2A adrenergic receptor) on the signal-receiving ends of brain cells. When these receptors are stimulated, they essentially close “leak channels” that would otherwise weaken the electrical signal passing between neurons. The result is stronger, more reliable firing in the brain networks that govern focus, planning, and self-regulation.
This mechanism, identified through research at Yale School of Medicine, explains why guanfacine can help with attention and emotional control even though it’s not a stimulant. It’s also why the medication can be useful for symptoms that stimulants don’t always address well, like emotional outbursts or difficulty winding down.
What “Extended-Release” Means
Guanfacine comes in two forms: immediate-release (IR) and extended-release (ER). The difference matters more than the name might suggest. The immediate-release version is absorbed and cleared quickly, which creates sharp peaks and valleys in blood levels throughout the day. This can mean inconsistent symptom control and more noticeable side effects at peak levels.
The extended-release tablet is made with rate-controlling polymers that slow absorption. It reaches peak concentration in the blood about 6 hours after you take it and has an average half-life of roughly 17 hours (with a range of 10 to 30 hours depending on the person). That flatter, more sustained drug level translates to steadier symptom control across the day with a single morning dose, rather than the multiple daily doses the immediate-release form requires.
FDA-Approved Uses
Guanfacine ER is FDA-approved for ADHD in two ways: as a standalone treatment or as an add-on to stimulant medications. Its efficacy was established in three controlled monotherapy trials and one adjunctive trial, each lasting up to 8 weeks, in children and adolescents ages 6 to 17. It has not been approved for children under 6.
In clinical practice, prescribers typically consider guanfacine ER in several specific situations: when stimulants cause intolerable side effects or are contraindicated, when ADHD comes with significant emotional dysregulation, aggression, tics, or sleep problems, or when a stimulant alone provides only a partial response. It can also be added to a stimulant to cover rebound symptoms that emerge as the stimulant wears off in the evening.
Common Side Effects
Because guanfacine was originally developed as a blood pressure medication, its most common side effects reflect that origin. Sleepiness is the most frequently reported issue, especially during the first few weeks of treatment. Fatigue and sedation are also common. These effects often improve as the body adjusts, but they’re the main reason prescribers start at a low dose and increase gradually.
Guanfacine ER also lowers heart rate and blood pressure. In one study, heart rate dropped by an average of about 12 beats per minute. Blood pressure reductions were smaller and not statistically significant in most trials, with systolic pressure dropping less than 1 mmHg and diastolic pressure dropping about 3.7 mmHg on average. Still, these cardiovascular effects are the reason baseline heart rate and blood pressure are typically checked before starting treatment and monitored periodically.
Drug Interactions to Know About
Guanfacine is broken down in the liver by a specific enzyme system. Medications that block this enzyme can cause guanfacine to build up in the body. In studies, one such inhibitor doubled the peak blood concentration of guanfacine and tripled overall drug exposure. If you’re taking a medication that inhibits this enzyme (certain antifungals and some antibiotics are common examples), your guanfacine dose may need to be reduced.
The reverse is also true. Medications that speed up this enzyme system can dramatically reduce guanfacine levels. One such drug cut peak guanfacine concentrations by more than half and reduced total exposure by 60 to 70 percent, potentially making the medication ineffective. In that case, a higher guanfacine dose may be needed.
Guanfacine can also interact with valproic acid, a medication used for seizures and mood stabilization. Co-administration can raise valproic acid levels significantly, and those levels drop again when guanfacine is tapered off. This interaction requires monitoring if both medications are used together.
Stopping Guanfacine ER Safely
The immediate-release form of guanfacine has a known association with rebound high blood pressure when stopped suddenly. The extended-release version appears to carry less of this risk. In a controlled study of healthy young adults taking up to 4 mg daily, abrupt discontinuation did not produce clinically significant blood pressure spikes compared to a gradual taper.
That said, gradual tapering is still standard practice. A typical taper schedule involves reducing the dose by 1 mg every few days over roughly two weeks. Even if rebound hypertension is unlikely with the ER formulation, tapering avoids the possibility of a sudden return of ADHD symptoms and gives the body time to readjust.
How It Compares to Stimulants
Guanfacine ER is not a replacement for stimulant medications in most cases. Stimulants remain the first-line treatment for ADHD because they tend to produce larger improvements in core attention and hyperactivity symptoms. Guanfacine ER fills a different role: it’s a solid option when stimulants aren’t appropriate, and it’s particularly useful as a complement to stimulants when emotional regulation, tics, or evening rebound symptoms are part of the picture.
One practical advantage of guanfacine ER is that it’s not a controlled substance. It has no abuse potential, which can matter for families or individuals who are concerned about stimulant misuse or who face logistical challenges with controlled substance prescriptions. It also doesn’t cause appetite suppression or the “wired” feeling some people experience with stimulants.